BioLight Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer

BioLight announced today that its CellDetect® non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories.  The CE marking recognizes the conformity of the CellDetect® non-invasive test for detecting recurrence of bladder cancer in urine with the relevant directive of the European Community. BioLight also announced that the European Patent Office has issued a patent related to the core of the CellDetect® technology.  The patent will be in effect until March 2027.

Link to complete article

Link to Newsroom

Comments are closed.